A Novel Eg5 Inhibitor (LY2523355) Causes Mitotic Arrest and Apoptosis in Cancer Cells and Shows Potent Antitumor Activity in Xenograft Tumor Models

Intervention of cancer cell mitosis by antitubulin drugs is among the most effective cancer chemotherapies. However, antitubulin drugs have dose-limiting side effects due to important functions of microtubules in resting normal cells and are often rendered ineffective by rapid emergence of resistance. Antimitotic agents with different mechanisms of action and improved safety profiles are needed as new treatment options. Mitosis-specific kinesin Eg5 represents an attractive anticancer target for discovering such new antimitotic agents, because Eg5 is essential only in mitotic progression and has no roles in resting, nondividing cells. Here, we show that a novel selective Eg5 inhibitor, LY2523355, has broad target-mediated anticancer activity in vitro and in vivo. LY2523355 arrests cancer cells at mitosis and causes rapid cell death that requires sustained spindle-assembly checkpoint (SAC) activation with a required threshold concentration. In vivo efficacy of LY2523355 is highly dose/schedule-dependent, achieving complete remission in a number of xenograft tumor models, including patient-derived xenograft (PDX) tumor models. We further establish that histone-H3 phosphorylation of tumor and proliferating skin cells is a promising pharmacodynamic biomarker for in vivo anticancer activity of LY2523355. Mol Cancer Ther; 14(11); 2463–72. ©2015 AACR.

[1]  Adam R. Johnson,et al.  Sensitivity to antitubulin chemotherapeutics is regulated by MCL1 and FBW7 , 2011, Nature.

[2]  R. Medema,et al.  Mechanisms of centrosome separation and bipolar spindle assembly. , 2010, Developmental cell.

[3]  C. Dumontet,et al.  Microtubule-binding agents: a dynamic field of cancer therapeutics , 2010, Nature Reviews Drug Discovery.

[4]  B. Tunquist,et al.  Mcl-1 Stability Determines Mitotic Cell Fate of Human Multiple Myeloma Tumor Cells Treated with the Kinesin Spindle Protein Inhibitor ARRY-520 , 2010, Molecular Cancer Therapeutics.

[5]  Min Liu,et al.  Ectopic expression of the microtubule‐dependent motor protein Eg5 promotes pancreatic tumourigenesis , 2010, The Journal of pathology.

[6]  A. Awada,et al.  Final analysis of a phase I single dose-escalation study of the novel polo-like kinase 1 inhibitor BI 6727 in patients with advanced solid tumors. , 2010 .

[7]  Jian Du,et al.  Cdk1 Activity Is Required for Mitotic Activation of Aurora A during G2/M Transition of Human Cells , 2010, The Journal of Biological Chemistry.

[8]  T. Chambers,et al.  Cyclin-Dependent Kinase 1-Mediated Bcl-xL/Bcl-2 Phosphorylation Acts as a Functional Link Coupling Mitotic Arrest and Apoptosis , 2009, Molecular and Cellular Biology.

[9]  V. Yang,et al.  Role of prolonged mitotic checkpoint activation in the formation and treatment of cancer. , 2009, Future oncology.

[10]  M. Roberge,et al.  Effects of chemical manipulation of mitotic arrest and slippage on cancer cell survival and proliferation , 2009, Cell cycle.

[11]  M. Hogarty,et al.  Mcl1 downregulation sensitizes neuroblastoma to cytotoxic chemotherapy and small molecule Bcl2-family antagonists , 2009, Cancer biology & therapy.

[12]  W. Taylor,et al.  Length of mitotic arrest induced by microtubule-stabilizing drugs determines cell death after mitotic exit , 2009, Molecular Cancer Therapeutics.

[13]  H. Saya,et al.  K858, a novel inhibitor of mitotic kinesin Eg5 and antitumor agent, induces cell death in cancer cells. , 2009, Cancer research.

[14]  G. Adolf,et al.  BI 6727, A Polo-like Kinase Inhibitor with Improved Pharmacokinetic Profile and Broad Antitumor Activity , 2009, Clinical Cancer Research.

[15]  D. Huszar,et al.  Kinesin motor proteins as targets for cancer therapy , 2009, Cancer and Metastasis Reviews.

[16]  G. Lajoie,et al.  Phosphorylation by Cdk1 Increases the Binding of Eg5 to Microtubules In Vitro and in Xenopus Egg Extract Spindles , 2008, PloS one.

[17]  Conly L. Rieder,et al.  Microtubules do not promote mitotic slippage when the spindle assembly checkpoint cannot be satisfied , 2008, The Journal of cell biology.

[18]  Min Liu,et al.  Validating the mitotic kinesin Eg5 as a therapeutic target in pancreatic cancer cells and tumor xenografts using a specific inhibitor. , 2008, Biochemical pharmacology.

[19]  T. Mitchison,et al.  Cell type variation in responses to antimitotic drugs that target microtubules and kinesin-5. , 2008, Cancer research.

[20]  M. Justice,et al.  Overexpression of Eg5 causes genomic instability and tumor formation in mice. , 2007, Cancer research.

[21]  Makoto Kinoshita,et al.  [Small molecule inhibitor of mitotic spindle bipolarity identified in a phenotype-based screen]. , 2007, Tanpakushitsu kakusan koso. Protein, nucleic acid, enzyme.

[22]  Jeffrey R. Jackson,et al.  Targeted anti-mitotic therapies: can we improve on tubulin agents? , 2007, Nature Reviews Cancer.

[23]  Conly L. Rieder,et al.  Mitotic Checkpoint Slippage in Humans Occurs via Cyclin B Destruction in the Presence of an Active Checkpoint , 2006, Current Biology.

[24]  Polly M. Fordyce,et al.  Individual dimers of the mitotic kinesin motor Eg5 step processively and support substantial loads in vitro , 2006, Nature Cell Biology.

[25]  Weikang Tao,et al.  Induction of apoptosis by an inhibitor of the mitotic kinesin KSP requires both activation of the spindle assembly checkpoint and mitotic slippage. , 2005, Cancer cell.

[26]  E. Peterman,et al.  The bipolar mitotic kinesin Eg5 moves on both microtubules that it crosslinks , 2005, Nature.

[27]  A. Marcus,et al.  Mitotic Kinesin Inhibitors Induce Mitotic Arrest and Cell Death in Taxol-resistant and -sensitive Cancer Cells* , 2005, Journal of Biological Chemistry.

[28]  E. Nigg,et al.  Cell cycle regulation of central spindle assembly , 2004, Nature.

[29]  K. Wood,et al.  Antitumor activity of a kinesin inhibitor. , 2004, Cancer research.

[30]  A. Maier,et al.  Clonogenic assay with established human tumour xenografts: correlation of in vitro to in vivo activity as a basis for anticancer drug discovery. , 2004, European journal of cancer.

[31]  Lawrence C Kuo,et al.  Inhibition of a mitotic motor protein: where, how, and conformational consequences. , 2004, Journal of molecular biology.

[32]  S. Endow,et al.  A new kinesin tree , 2004, Journal of Cell Science.

[33]  Susan Band Horwitz,et al.  Mechanisms of Taxol resistance related to microtubules , 2003, Oncogene.

[34]  Hongtao Yu,et al.  Regulation of APC-Cdc20 by the spindle checkpoint. , 2002, Current opinion in cell biology.

[35]  T. Kapoor,et al.  Probing Spindle Assembly Mechanisms with Monastrol, a Small Molecule Inhibitor of the Mitotic Kinesin, Eg5 , 2000, The Journal of cell biology.

[36]  R. Uzbekov,et al.  Cell cycle analysis and synchronization of the Xenopus laevis XL2 cell line: Study of the kinesin related protein XlEg5 , 1999, Microscopy research and technique.

[37]  S. Lobert.  Neurotoxicity in cancer chemotherapy: vinca alkaloids. , 1997, Critical care nurse.

[38]  G. C. Rogers,et al.  The bimC family of kinesins: essential bipolar mitotic motors driving centrosome separation. , 1997, Biochimica et biophysica acta.

[39]  R. Baskin,et al.  A bipolar kinesin , 1996, Nature.

[40]  H. Lane,et al.  Phosphorylation by p34cdc2 regulates spindle association of human Eg5, a kinesin-related motor essential for bipolar spindle formation in vivo , 1995, Cell.

[41]  T. Mitchison,et al.  Mutations in the kinesin-like protein Eg5 disrupting localization to the mitotic spindle. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[42]  Timothy J. Mitchison,et al.  Mitotic spindle organization by a plus-end-directed microtubule motor , 1992, Nature.

[43]  A. Awada,et al.  A phase I, dose-escalation study of the novel Polo-like kinase inhibitor volasertib (BI 6727) in patients with advanced solid tumours. , 2012, European journal of cancer.

[44]  R. Weichselbaum,et al.  Predictors of competing mortality in advanced head and neck cancer. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[45]  S. Endow,et al.  A kinesin family tree. , 2000, Journal of cell science.